Risdiplam is an oral mRNA splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) by modulating RNA splicing to increase the production of functional SMN2 protein. To support rigorous… Read more
![Chemical structure of 2,8-Dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1825352-86-0-28-Dimethyl-6-4455-tetramethyl-132-dioxaborolan-2-ylimidazo12-bpyridazine.png&w=3840&q=75)
![Chemical structure of 2-(2,8-Dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(4-hydroxy-4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2250441-24-6-2-28-Dimethylimidazo12-bpyridazin-6-yl-7-4-hydroxy-47-diazaspiro2.5octan-7-yl-4H-pyrido12-apyrimidin-4-one.png&w=3840&q=75)
![Chemical structure of 2-(2,8-Dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(4-nitroso-4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2-28-Dimethylimidazo12-bpyridazin-6-yl-7-4-nitroso-47-diazaspiro2.5octan-7-yl-4H-pyrido12-apyrimidin-4-one.png&w=3840&q=75)
![Chemical structure of 2-(2,8-Dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1825352-87-1-2-28-Dimethylimidazo12-bpyridazin-6-yl-7-fluoro-4H-pyrido12-apyrimidin-4-one.png&w=3840&q=75)

![Chemical structure of 2-Chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1449598-86-0-2-Chloro-7-fluoro-4H-pyrido12-apyrimidin-4-one.png&w=3840&q=75)


![Chemical structure of 4,7-Diazaspiro[2.5]octane Dihydrochloride](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F145122-56-1-47-Diazaspiro2.5octane-Dihydrochloride.png&w=3840&q=75)
![Chemical structure of 4-Boc-4,7-diazaspiro[2.5]octane](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F674792-08-6-4-Boc-47-diazaspiro2.5octane.png&w=3840&q=75)


![Chemical structure of 6-Chloro-2,8-dimethylimidazo[1,2-b]pyridazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F17412-23-6-6-Chloro-28-dimethylimidazo12-bpyridazine.png&w=3840&q=75)


![Chemical structure of 7-(Phenylmethyl)-4,7-diazaspiro[2.5]octane](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1222106-45-7-7-Phenylmethyl-47-diazaspiro2.5octane.png&w=3840&q=75)













![Chemical structure of tert-Butyl 4,7-diazaspiro[2.5]octane-7-carboxylate Hydrochloride](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1462383-16-9-tert-Butyl-47-diazaspiro2.5octane-7-carboxylate-Hydrochloride.png&w=3840&q=75)
![Chemical structure of tert-Butyl 4-nitroso-4,7-diazaspiro[2.5]octane-7-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2Ftert-Butyl-4-nitroso-47-diazaspiro2.5octane-7-carboxylate.png&w=3840&q=75)
![Chemical structure of tert-Butyl 7-(2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl)-4,7-diazaspiro[2.5]octane-4-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2133298-74-3-tert-Butyl-7-2-28-dimethylimidazo12-bpyridazin-6-yl-4-oxo-4H-pyrido12-apyrimidin-7-yl-47-diazaspiro2.5octane-4-carboxylate.png&w=3840&q=75)
![Chemical structure of tert-Butyl 7-(2-hydroxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl)-4,7-diazaspiro[2.5]octane-4-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2133298-72-1-tert-Butyl-7-2-hydroxy-4-oxo-4H-pyrido12-apyrimidin-7-yl-47-diazaspiro2.5octane-4-carboxylate.png&w=3840&q=75)
![Chemical structure of tert-Butyl 7-(4-oxo-2-(tosyloxy)-4H-pyrido[1,2-a]pyrimidin-7-yl)-4,7-diazaspiro[2.5]octane-4-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2133298-73-2-tert-Butyl-7-4-oxo-2-tosyloxy-4H-pyrido12-apyrimidin-7-yl-47-diazaspiro2.5octane-4-carboxylate.png&w=3840&q=75)
![Chemical structure of tert-Butyl 7-benzyl-4,7-diazaspiro[2.5]octane-4-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F674792-03-1-tert-Butyl-7-benzyl-47-diazaspiro2.5octane-4-carboxylate.png&w=3840&q=75)
Risdiplam is an oral mRNA splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) by modulating RNA splicing to increase the production of functional SMN2 protein. To support rigorous quality control and regulatory compliance, pharmaceutical laboratories require high-quality reference standards, including synthetic intermediates, process-related impurities, and degradation products associated with this active pharmaceutical ingredient. These compounds are essential for accurate impurity profiling and analytical method validation, ensuring safety throughout the manufacturing lifecycle. Additionally, stable isotope-labelled compounds are available to serve as precise internal standards for mass spectrometry-based assays. By utilizing these characterized reference materials, analytical chemists can effectively identify and quantify related substances, maintaining the therapeutic efficacy and purity of pharmaceutical products.